8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

November 20, 2020

(Date of Report—date of earliest event reported)

 

 

InMed Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

British Columbia

(State or Other Jurisdiction of

Incorporation or Organization)

 

001-39685

(Commission File Number)

 

98-1428279

(I.R.S. Employer

Identification No.)

Suite 310 – 815 W. Hastings Street

Vancouver, B.C., Canada

(Address of Principal Executive Offices)

   

V6C 1B4

(Zip Code)

(604) 669-7207

(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Shares, no par value   INM   The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.07: Submission of Matters to a Vote of Security Holders

On November 20, 2020, InMed Pharmaceuticals Inc., or the “Corporation”, held its Annual and Special General Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below:

Proposal No. 1 – Election of Directors

The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2021 Annual General Meeting:

 

Nominee

   Votes For      % Votes For      Votes
Withheld
     %Votes
Withheld
     Broker
Non-Votes
 

Eric A. Adams

     639,176        90.84        64,464        9.16        1,672,478  

Adam Cutler

     654,431        93.01        49,209        6.99        1,672,478  

William J. Garner

     644,945        91.66        58,695        8.34        1,672,478  

Andrew Hull

     654,149        92.97        49,491        7.03        1,672,478  

Catherine Sazdanoff

     653,532        92.88        50,108        7.12        1,672,478  

Proposal No. 2 – Appointment of Independent Registered Public Accounting Firm

The Corporation’s shareholders voted to approve the appointment of KPMG LLP as the independent registered public accounting firm of the Corporation until the next annual shareholders’ meeting or until a successor is named.

 

Votes For

   % Votes For      Vote Against      % Votes Against      Abstain      Broker Non-
Votes
 

2,316,634

     97.50        0        0.00        59,484        0  

Proposal No. 3 – Amendment of Stock Option Plan

The Corporation’s shareholders voted to approve an amendment to the Corporation’s stock option plan in order to (1) update the definition of “Blackout Period” and (2) extend the period after a Blackout Period that an option may be exercised.

 

Votes For

   % Votes For      Vote Against      % Votes Against      Abstain      Broker Non-
Votes
 

577,223

     82.03        126,417        17.97        0        1,672,478  

Proposal No. 4 – Amendment to Articles

The Corporation’s shareholders voted to approve an amendment to Section 11.3 of the Articles of the Corporation that increases the quorum for any meeting of shareholders to two persons present at the opening of the meeting who are entitled to vote thereat either as shareholders or as proxy holders and holding or representing not less than 33-1/3% of the outstanding common shares entitled to be voted at the meeting.

 

Votes For

   % Votes For      Vote Against      % Votes Against      Abstain      Broker Non-
Votes
 

645,591

     91.75        58,049        8.25        0        1,672,478  

 

2


Item 9.01 Exhibits.

(d) Exhibits.

 

Exhibit 99.1.    News release, dated November 24, 2020

 

3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:    November 24, 2020

 

 

INMED PHARMACEUTICALS INC.
By:   /s/ Bruce Colwill
Name:   Bruce Colwill
Title:   Chief Financial Officer

 

4

EX-99.1

Exhibit 99.1

 

LOGO

  

TSX:IN

NASDAQ:INM

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

InMed Announces Election of Directors

Vancouver, BC – November 24, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today confirmed that, at its annual general and special meeting of shareholders held on November 20, 2020 (the “Meeting”), all of the matters put forward before shareholders for consideration and approval as set out in InMed’s notice of meeting and management information circular, dated October 7, 2020, were approved by the shareholders. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:

 

Director

   Votes For     Withheld Votes  
   Number      Percentage     Number      Percentage  

Eric A. Adams

     639,176        90.84     64,464        9.16

Adam Cutler

     654,431        93.01     49,209        6.99

William J. Garner

     644,945        91.66     58,695        8.34

Andrew Hull

     654,149        92.97     49,491        7.03

Catherine Sazdanoff

     653,532        92.88     50,108        7.12

InMed filed a report of voting results on SEDAR at www.sedar.com on November 24, 2020.

About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.

Investor Contact:

InMed Pharmaceuticals Inc.

Brendan Payne, Director of Investor Relations

T:    +1.604.669.7207

E:    info@inmedpharma.com

Edison Advisors for InMed Pharmaceuticals

Joe Green/Laine Yonker

T:    +1.646.653.7030/+1.646.760.0321

E:    jgreen@edisongroup.com / lyonker@edisongroup.com


Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: leading the way in the clinical development of CBN; developing a pipeline of cannabinoid-based medications in diseases with high unmet medical need; and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.